

LETTER TO THE EDITOR

Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses

Dear editor,

Lung carcinoma is responsible for the highest fatality rate among cancer-related deaths globally, with lung adenocarcinoma (LADC) emerging as the prevailing subtype. LADC is characterized by two distinctive attributes in individuals of Asian ancestry: firstly, Asian patients with LADC are more frequently non-smokers (approximately 40%) than their European counterparts (around 10%) [1]; secondly, approximately 50% of Asian LADC patients have oncogenic mutations in the epidermal growth factor receptor (*EGFR*) gene, whereas this frequency is around 10% in European and American patients [2]. Hence, it is plausible that risk factors exerting a more pronounced influence in Asian than in European/American populations contribute to LADC pathogenesis, irrespective of smoking status. To date, over 50 genomic loci associated with heightened susceptibility to lung carcinoma have been unearthed through genome-wide association studies (GWAS) investigating single nucleotide polymorphisms (SNPs) in East Asian and European/American patients [2–5]. A subset of these loci, including 5p15 (telomerase reverse transcriptase, *TERT*) and 3q28 (tumor protein p63, *TP63*), are associated with LADC risk in both populations. Hence, despite genetic disparities between Caucasian and Asian populations, the

populations share genetic factors contributing to lung carcinoma susceptibility.

We performed a meta-analysis encompassing two novel GWAS, comprising 5,416 individuals diagnosed with LADC and 29,696 control subjects (Supplementary Tables S1–S2, Supplementary Figure S1). Additionally, we compared susceptibility loci identified in European ancestry populations with our GWAS data. Five variants were associated with LADC risk in both our GWAS ($P < 5.0 \times 10^{-6}$) and a previous GWAS meta-analysis [3] (Supplementary Table S3). We also compared our findings with top associated SNPs from the latest GWAS [5] (Supplementary Table S4). Subsequently, the most strongly associated SNPs on conditional analysis in non-major histocompatibility complex (HLA) (Supplementary Table S5, Supplementary Figure S2) and HLA regions (Supplementary Table S6, Supplementary Figure S3) were validated in an independent dataset comprising 11,670 patients with LADC and 121,958 controls (Supplementary Figure S4). We detected significant associations of 19 genomic loci and LADC risk, characterized by highly significant P values (6.9×10^{-11} to 4.8×10^{-134}). Notably, four of these loci harbor three genes, telomerase RNA component (*TERC*), *TERT*, and protection of telomeres 1 (*POT1*), involved in regulating telomere maintenance (Supplementary Table S7). Associations with 10 loci previously reported in Asian populations (including two loci in *TERT*) [2, 4] and two loci reported in a Caucasian population [3] were validated in the present study (Supplementary Table S7). Additionally, we identified seven novel associated loci: protein tyrosine phosphatase receptor type G (*PTPRG*), *TERC*, butyrophilin subfamily 2 member A1 (*BTN2A1*), major histocompatibility complex, class I, C (*HLA-C*), major histocompatibility complex, class II, DQ beta 1 (*HLA-DQB1*), BCL2 antagonist/killer 1 (*BAK1*), and ankyrin repeat and SOCS box containing 15 (*ASB15*) (Supplementary Table S7).

We also inferred the biological effects of other LADC risk-associated SNP-containing loci identified in the

List of abbreviations: GWAS, genome-wide association studies; LADC, lung adenocarcinoma; WGS, whole genome sequencing; SNP, single nucleotide polymorphism; EGFR, epidermal growth factor receptor; TERT, telomerase reverse transcriptase; TP63, tumor protein p63; TERC, telomerase RNA component; POT1, protection of telomeres 1; PTPRG, protein tyrosine phosphatase receptor type G; BTN2A1, butyrophilin subfamily 2 member A1; HLA-C, major histocompatibility complex, class I, C; HLA-DQB1, major histocompatibility complex, class II, DQ beta 1; BAK1, BCL2 antagonist/killer 1; ASB15, ankyrin repeat and SOCS box containing 15; SECISBP2L, SECIS binding protein 2 like; TERF1, telomeric repeat binding factor 1; TINP2, TERF1 interacting nuclear factor 2; OBFC1, OB-fold-containing 1; TRF1, telomeric repeat binding factor 1; RAPI, TERF2 interacting protein; LTL, leukocyte telomere length.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Cancer Communications* published by John Wiley & Sons Australia, Ltd on behalf of SUN YAT-SEN UNIVERSITY CANCER CENTER.




FIGURE 1 Association of novel susceptibility loci with risk for lung adenocarcinoma according to *EGFR* mutation types and association between genotype and leukocyte telomere length. (A) A Forest plot showing associations between 19 SNPs and the presence or absence of *EGFR* mutations. Odds ratios were adjusted for age, sex, smoking status (never vs. ever smoking), and the top five principal components. Combined meta-analysis was performed using a fixed-effects model. *P*-values of SNPs that differed significantly between patients with LADC with and without *EGFR* mutations in case-case analysis are shown. (B) Association between *TERC*, *TERT*, and *POT1* genotypes and LTL. (C) Association between LADC risk and LTL in 19 LADC risk-associated SNPs. (D) Association between SNPs in telomere maintenance genes and LTL in our cohort (X-axis) and in GWAS catalog data (Y-axis).

Abbreviations: *EGFR*, epithelial growth factor receptor; Ctrl, control; KGP p3, 1000 genomes project phase 3; RSQR, imputation quality; LADC, lung adenocarcinoma; LTL, leukocyte telomere length; *TERC*, telomerase RNA component; *TERT*, telomerase reverse transcriptase; *POT1*, protection of telomeres 1; TL, telomere length; SNP, single nucleotide polymorphism; *TINF2*, TERF1 interacting nuclear factor 2; *OBFC1*, OB-fold-containing 1.

present study through differential expression analysis in normal lung or blood cells: SECIS-binding protein 2-like (*SECISBP2L*; which encodes a putative tumor suppressor protein substrate of Aurora-A kinase), *BAK1* (encoding a pro-apoptotic BCL2 family protein), and *BTN2A1* (encoding a butyrophilin-like protein involved in regulation of $\gamma\delta$ T-cell development and differentiation) (Supplementary Figure S5). Our data indicate that the identified risk-associated loci likely exert an impact on LADC development and immune evasion. Furthermore, we assessed the relationship between the 19 significantly associated

SNPs and LADC risk based on somatic *EGFR* mutations in tumor cells (Figure 1A and Supplementary Table S8). Intriguingly, 15 of the 19 SNPs had higher odds ratios in patients with *EGFR*-mutated tumors than in those without such mutations (Supplementary Table S9). Notably, the differences in association according to somatic *EGFR* mutations attained statistical significance for *TERT* and HLA-class II SNPs, reinforcing findings from our previous small-scale GWAS [2]; however, further validation studies are needed to more accurately assess the associations of these SNPs with risk of LADC with *EGFR* mutations.

The associations between SNPs in three genes responsible for telomere maintenance (*TERT*, *TERC*, and *POT1*) and risk of LADC prompted us to explore how these genetic variations influence telomere biology. To accomplish this, we conducted whole-genome sequencing (WGS) of tumor and non-tumor DNA samples obtained from 964 patients with LADC (Supplementary Table S10). Consistent with previous investigations [6], we found that women had longer leukocyte telomere lengths (LTLs) than men, and that LTLs decreased with advancing age, thereby validating the accuracy of our LTL estimation method (Supplementary Figure S6). Notably, the presence of *TERT* and *TERC* risk variants tended to be indicative of elevated LTL ($P < 0.01$) regardless of sex (Figure 1B, Supplementary Figure S7, Supplementary Table S11). Further, variants in the *TERT*, *TERC*, and *POT1* genes were nominally associated with LADC risk and longer LTL ($P < 0.01$) (Figure 1C). Furthermore, we investigated the associations between 398 variants previously linked to both LADC risk and LTL (compiled from the GWAS catalog, <https://www.ebi.ac.uk/gwas/>) with LTL in our cohort. Intriguingly, we observed that four risk variants in three additional genes involved in telomere maintenance, namely, telomeric repeat-binding factor 1 (*TERF1*), TERF1-interacting nuclear factor 2 (*TINF2*), and OB-fold-containing 1 (*OBFC1*), exhibited a tendency toward association with longer LTLs ($P < 0.01$) (Figure 1D, Supplementary Table S12) and LADC risk. Further validation studies are needed. Physiologically, LTL is tightly governed by telomerase enzymes, including *TERC*, *TERT*, and *OBFC1*, along with shelterin proteins, such as telomeric repeat-binding factor 1 (TRF1), TERF2-interacting protein (RAP1), *TERF1*, and *POT1*, which bind to specific DNA sequences at chromosome termini [6]. The current discovery aligns harmoniously with a recent study indicating that hereditary *POT1* mutations were associated with extended telomere length and conferred a predisposition to a familial clonal hematopoiesis syndrome accompanied by development of various solid tumors [7]. A recent Mendelian randomization analysis study established a positive association between longer telomere length and an elevated risk of developing LADC [8]. Building on this discovery, our findings shed further light by demonstrating that common variants within telomere maintenance genes contribute to telomere elongation and increase susceptibility to LADC in Asian populations. Intriguingly, these variants exhibited associations with LTL, while demonstrating no association with telomere length, structural variant count, or tumor mutational burden in 642 patients with LADC (Supplementary Figure S8, Supplementary Table S13). These findings imply that genetic polymorphisms in telomere maintenance genes facilitate telomere elon-

gation, thus prolonging lung epithelial cell survival. The extended lifespan of these cells increases the likelihood of their transformation into malignant cells over time, without influencing somatic alterations during tumor initiation and progression.

Here, we conducted an extensive GWAS, leading to the identification of 19 susceptibility loci associated with LADC. By WGS analysis of 964 samples from patients with LADC, we discovered that risk alleles within the *TERT* and *TERC* genes were linked to elongated telomeres in non-tumor cells, while having no impact on telomere length, mutation status, or structural characteristics of tumor cells. These findings indicate that the presence of long telomeres, conferred by genetic polymorphisms in individuals of Asian descent, fosters the survival of lung epithelial cells and heightens their propensity to undergo malignant transformation. Further elucidation of the distinct and cumulative effects of the 19 LADC risk-associated loci will significantly augment our comprehension of this disease, thereby advancing endeavors toward its treatment and prevention.

DECLARATIONS

AUTHOR CONTRIBUTIONS

Ko.S. and Ta.K. undertook conceptualization. GWAS was performed by Ko.S.; A.T.; Yu.M.; Y.D.; T.Ka.; M.K.; H.I.; F.M.; Y.K.; and Ke.M. Clinical and/or genetic information on study subjects was collected by H.K.; S.M.; H.H.; A.G.; Ta.H.; Ki.S.; M.Sa.; Yu.O.; S.W.; K.G.; M.T.; Kat.T.; Ma.K.; Yoh.M.; Ka.T.; Hi.S.; D.M.; Tak.Y.; Ta.M.; Tai.Y.; Y.G.; Ta.Yo.; Ta.Ya.; M.So.; S.To.; K.Y.; Ka.M.; F.T.; M.H.; N.F.; S.S.N.; N.M.; T.S.; Y.N.; K.Ku.; K.Tak.; K.Tan.; Y.Y.; Ku.S.; T.H.; T.M.; Ha.N.; T.N.; Y.O.; N.S.; Y.M.; K.Ku.; K.Take.; Ko.T.; Y.Y.; Ku.S.; T.H.; Tai.M.; H.N.; T.Y.; T.N.; Y.O.; K.Im.; Yo.M.; K.O.; Ka.I.; K.W.; A.S.; M.Y.; M.I.; Ko.M.; J.I.; and Y.M. Omics analysis was undertaken by Ko.S.; S.K.; D.T.; A.S.; S.Ta.; T.A.; A.T.; M.M.; Y.S.; H.S.; T.Y.; M.A.; H.T.; K.Im.; K.Taka.; K.Ko.; H.N.; R.H.; and Y.K. **All authors** reviewed the manuscript draft and revised it critically for intellectual content. **All authors** approved the final version of the manuscript to be published.

ACKNOWLEDGMENTS

We thank all of the subjects for participating in the study, as well as the collaborating physicians for assisting with sample collection. We are grateful to the National Cancer Center Biobank, BioBank Japan, Tohoku Medical Megabank Organization (ToMMo), Iwate Tohoku Medical Megabank Organization (Iwate Medical University), the Japan Public Health Center (JPHC)-based Prospective Study, the Japan Multi-Institutional Collaborative

Cohort (J-MICC) Study, and Kanagawa Cancer Center-BioSpecimen Center for their invaluable contributions to collecting samples. We thank Yoko Odaka, Suenori Chiku, Noriko Abe, Sachiko Miura, Chizu Kina, Tsuyuka Ohtsuki, Yuka Asami, Y. Yukawa, Y. Yokoyama, and technical staff at the Center for Genome Medicine, National Cancer Center (NCC), for providing technical/methodological assistance. This research was supported in part by the Japan Agency for Medical Research and Development (AMED) (JP15ck0106096 to TK), Japan Science and Technology Agency (JST) Core Research for Evolutionary Science and Technology (JPMJCR1689 to RH) and Artificial Intelligence, Big Data, IoT, Cyber Security Integration Project of the Public/Private R&D Investment Strategic Expansion Program (JPMJCR18Y4 to RH), the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (S) (17H06162 to HN), Grant-in-Aid for Scientific Research (B) (20H03695 to KS), Grants-in-Aid for the Tailor-Made Medical Treatment Program (BioBank Japan Project) from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), Princess Takamatsu Cancer Research Fund, and National Cancer Center Research and Development Fund (NCC Biobank and NCC Core Facility). The J-MICC study was supported by Grants-in-Aid for Scientific Research for Priority Areas of Cancer (No. 17015018 to KW) and Innovative Areas (No. 221S0001 to KW) from MEXT, and by JSPS Grant-in-Aid for Scientific Research Grant (No. 16H06277 [CoBiA]). The JPHC Study was supported by National Cancer Center Research and Development Fund since 2011 (latest grant number: 2020-J4) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan (1989-2010). ToMMo is supported in part by MEXT-JST and AMED (most recent grant numbers: JP20km0105001 and JP20km0105002). Iwate Tohoku Medical Megabank Organization (Iwate Medical University) is supported in part by MEXT-JST and AMED (most recent grant numbers: JP20km0105003 and JP20km0105004).

CONFLICT OF INTEREST STATEMENT

The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

All participating studies obtained informed consent from the participants by following the protocols approved by their institutional ethical committees. The present study was approved by the ethical committees of each participating institution (ethics approval numbers: 2005-109, 2013-060, 2015-159, 2015-278, 2011-044).

CONSENT FOR PUBLICATION

Not applicable.

DATA AVAILABILITY STATEMENT

Genome data are available from the National Bioscience Database Center (NBDC) Human Database (research ID: hum0014 and hum0012.v1). Summary GWAS1 and GWAS2 data can be freely downloaded from <https://epi.ncc.go.jp/cgi-bin/cms/public/index.cgi/jcge/en/download/index>.

Kouya Shiraishi^{1,2} 
 Atsushi Takahashi^{3,4}
 Yukihide Momozawa⁵
 Yataro Daigo^{6,7}
 Syuzo Kaneko⁸
 Takahisa Kawaguchi⁹
 Hideo Kunitoh¹⁰
 Shingo Matsumoto¹¹
 Hidehito Horinouchi¹²
 Akiteru Goto¹³
 Takayuki Honda¹⁴
 Kimihiro Shimizu^{15,16}
 Masahiro Torasawa^{1,12}
 Daisuke Takayanagi¹ 
 Motonobu Saito¹⁷
 Akira Saito¹⁸
 Yuichiro Ohe¹²
 Shun-ichi Watanabe¹⁹
 Koichi Goto¹¹
 Masahiro Tsuboi²⁰
 Katsuya Tsuchihara²¹
 Sadaaki Takata⁵ 
 Tomomi Aoi⁵
 Atsushi Takano⁶
 Masashi Kobayashi²²
 Yohei Miyagi²³
 Kazumi Tanaka¹⁶
 Hiroyuki Suzuki²⁴
 Daichi Maeda¹³
 Takumi Yamaura²⁴
 Maiko Matsuda¹
 Yoko Shimada¹
 Takaaki Mizuno^{1,12}
 Hiromi Sakamoto²⁵
 Teruhiko Yoshida²⁶
 Yasushi Goto¹²
 Tatsuya Yoshida¹²
 Taiki Yamaji²⁷
 Makoto Sonobe²⁸
 Shinichi Toyooka²⁹
 Kazue Yoneda³⁰
 Katsuhiko Masago³¹
 Fumihiro Tanaka³⁰
 Megumi Hara³²
 Nobuo Fuse³³
 Satoshi S. Nishizuka³⁴

Noriko Motoi³⁵
 Norie Sawada²⁷
 Yuichiro Nishida³² 
 Kazuki Kumada³³
 Kenji Takeuchi³⁶
 Kozo Tanno³⁴
 Yasushi Yatabe³⁵
 Kuniko Sunami¹
 Tomoyuki Hishida^{20,37}
 Yasunari Miyazaki¹⁴
 Hidemi Ito³⁸
 Mitsuhiro Amemiya¹⁸
 Hirohiko Totsuka¹⁸
 Haruhiko Nakayama³⁹
 Tomoyuki Yokose⁴⁰
 Kazuyoshi Ishigaki³
 Toshiteru Nagashima¹⁶
 Yoichi Ohtaki¹⁶
 Kazuhiro Imai⁴¹
 Ken Takasawa⁸
 Yoshihiro Minamiya⁴¹
 Kazuma Kobayashi⁸
 Kenichi Okubo²²
 Kenji Wakai³⁶
 Atsushi Shimizu³⁴
 Masayuki Yamamoto³³
 Motoki Iwasaki^{27,42}
 Koichi Matsuda⁴³
 Johji Inazawa⁴⁴
 Yuichi Shiraishi⁴⁵
 Hiroyoshi Nishikawa⁴⁶
 Yoshinori Murakami⁴⁷
 Michiaki Kubo⁵
 Fumihiko Matsuda⁹
 Yoichiro Kamatani³
 Ryuji Hamamoto⁸ 
 Keitaro Matsuo⁴⁸
 Takashi Kohno¹ 

¹Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan

²Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan

³Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan

⁴Department of Genomic Medicine, Research Institute, National Cerebral and Cardiovascular Center, Osaka, Japan

⁵Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan

⁶Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

⁷Department of Medical Oncology and Cancer Center, and Center for Advanced Medicine against Cancer, Shiga University of Medical Science, Otsu, Japan

⁸Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan

⁹Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

¹⁰Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan

¹¹Department of Thoracic Oncology, National Cancer Center Hospital East, Japan

¹²Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

¹³Department of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan

¹⁴Department of Respiratory Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

¹⁵Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan

¹⁶Department of General Surgical Science, Division of General Thoracic Surgery, Gunma University Graduate School of Medicine, Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan

¹⁷Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan

¹⁸StaGen Co., Ltd, Tokyo, Japan

¹⁹Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan

²⁰Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan

²¹Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Chiba, Japan

²²Department of Thoracic Surgery, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

²³Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan

²⁴Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan

²⁵Fundamental Innovative Oncology Core Center, National Cancer Center Research Institute, Tokyo, Japan

²⁶Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan

²⁷Division of Epidemiology, National Cancer Center Institute for Cancer Control, Tokyo, Japan

²⁸Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

²⁹Departments of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

³⁰Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan

³¹Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan

³²Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan

³³Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan

³⁴Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan

³⁵Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan

³⁶Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

³⁷Division of Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan

³⁸Division of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, Japan

³⁹Department of Thoracic Surgery, Kanagawa Cancer Center, Kanagawa, Japan

⁴⁰Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan

⁴¹Department of Thoracic Surgery, Graduate School of Medicine, Akita University, Akita, Japan

⁴²Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan

⁴³Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan

⁴⁴Department of Molecular Cytogenetics, Medical Research Institute and Bioresource Research Center, Tokyo Medical and Dental University, Tokyo, Japan

⁴⁵Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan

⁴⁶Division of Cancer Immunology, Research Institute, National Cancer Center, Tokyo, Japan

⁴⁷Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

⁴⁸Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan

Correspondence

Takashi Kohno and Kouya Shiraishi, Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Email: tkkohno@ncc.go.jp and kshiraish@ncc.go.jp

Keitaro Matsuo, Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.
Email: kmatsuo@aichi-cc.jp

Ryuji Hamamoto, Division of Medical AI Research and Development, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Email: rhamamot@ncc.go.jp

Yoichiro Kamatani, Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
Email: yoichiro.kamatani@riken.jp

Fumihiko Matsuda, Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Yoshida-honmachi, Sakyo-ku, Kyoto-shi, 606-8501, Japan.
Email: fumi@genome.med.kyoto-u.ac.jp

ORCID

Kouya Shiraishi  <https://orcid.org/0000-0002-5821-7400>

Daisuke Takayanagi  <https://orcid.org/0000-0001-9644-9782>

Sadaaki Takata  <https://orcid.org/0000-0002-5354-5341>
Yuichiro Nishida  <https://orcid.org/0000-0003-2320-7234>

Ryuji Hamamoto  <https://orcid.org/0000-0002-2632-1334>

Takashi Kohno  <https://orcid.org/0000-0002-5371-706X>

REFERENCES

1. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. *Nat Rev Cancer* 2007;7(10):778–90.
2. Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, et al. Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. *Nat Commun* 2016;7:12451.
3. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet* 2017;49(7):1126–32.
4. Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, et al. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. *Nat Commun* 2023;14(1):3043.
5. Byun J, Han Y, Li Y, Xia J, Long E, Choi J, et al. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. *Nat Genet* 2022;54(8):1167–77.
6. Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. *Science* 2015;350(6265):1193–98.
7. DeBoy EA, Tassia MG, Schratz KE, Yan SM, Cosner ZL, McNally EJ, et al. Familial Clonal Hematopoiesis in a Long Telomere Syndrome. *N Engl J Med* 2023;388(26):2422–33.

8. Markozannes G, Kanellopoulou A, Dimopoulou O, Kosmidis D, Zhang X, Wang L, et al. Systematic review of Mendelian randomization studies on risk of cancer. *BMC Med* 2022; 20(1):41.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.